Drug Trial Radar · NCT06612775
A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Aug 14, 2024
Primary completion
Sep 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Shanghai Zhimeng Biopharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.
Conditions
- Focal Epilepsy
Interventions
Test drug CB03-154 5mg groupDrug
CB03-154 tablet (5mg/tablet) once daily.
Test drug CB03-154 10mg groupDrug
Two CB03-154 tablets (5mg/tablet) once daily.
Test drug CB03-154 20mg groupDrug
Four CB03-154 tablets (5mg/tablet) once daily.
Placebo groupDrug
Four Placebo tablets once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the efficacy of CB03-154 compared to placebo on focal seizure frequency in adults with focal epilepsy taking 1 to 3 AEDs in the double-blind period (DBP).Time frame: From baseline to the entire period of double-blind period, assessed up to 20 weeks.
- To assess the safety and tolerability by evaluating the frequency and severity of adverse events (AEs) /serious adverse events (SAEs) of CB03-154 in adults with focal epilepsy taking 1 to 3 AEDs in the DBP.Time frame: From the entire period of double-blind period of 12 weeks to the post-treatment follow-up period of 2 weeks(+7 days), assessed up to 17 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Alfred Health
Melbourne, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.